EPAS1 and nonpapillary renal cell carcinoma: Further to this a biomarker that accurately quantifies HIF2α-HIF1β interaction could provide a useful tool to determine patients with solid tumours other than ccRCC that frequently exhibit hypoxia and may be sensitive to HIF2α inhibitors.